Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
2.680
+0.270 (11.20%)
At close: Aug 22, 2025, 4:00 PM
2.700
+0.020 (0.75%)
Pre-market: Aug 25, 2025, 8:59 AM EDT
Outlook Therapeutics Employees
Outlook Therapeutics had 23 employees as of September 30, 2024. The number of employees decreased by 1 or -4.17% compared to the previous year.
Employees
23
Change (1Y)
-1
Growth (1Y)
-4.17%
Revenue / Employee
$65,449
Profits / Employee
-$1,888,731
Market Cap
119.04M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 23 | -1 | -4.17% |
Sep 30, 2023 | 24 | 7 | 41.18% |
Sep 30, 2022 | 17 | 8 | 88.89% |
Sep 30, 2021 | 9 | 1 | 12.50% |
Sep 30, 2020 | 8 | -6 | -42.86% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
OTLK News
- 1 day ago - Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision - Seeking Alpha
- 11 days ago - Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire
- 7 weeks ago - Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer - GlobeNewsWire
- 2 months ago - Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - GlobeNewsWire
- 3 months ago - Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - GlobeNewsWire